Mirati Therapeutics Growth, Revenue, Number of Employees and Funding
Revenue & Financials
- Mirati Therapeutics's revenue is currently $12.9M per year.
- Mirati Therapeutics received $130.0M in venture funding in January 2019.
- Mirati Therapeutics's revenue per employee is $187333
- Mirati Therapeutics's total funding is $101.3M.
- Mirati Therapeutics has 69 Employees.
- Mirati Therapeutics grew their employee count by 33% last year.
- Mirati Therapeutics currently has 9 job openings.
What Is Mirati Therapeutics?
Mirati Therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. Mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. The Mirati team uses a blueprint - proven by their prior work - for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications.keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$23.9M||166||8%|
|Full Spectrum A...||$5.7M||39||5%|
Mirati Therapeutics News
Mirati Therapeutics Inc (NASDAQ:MRTX)'s share price reached a new 52-week high on Monday . The stock traded as high as $80.00 and last
Mirati Therapeutics, Inc. (NASDAQ:MRTX) shares ended at $76.31 with 1.09 mln shares exchanging hands. That puts the market capitalization
28, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial
Mirati Therapeutics Funding
|2013-10-17||$Undisclosed||Undisclosed||Leerink Swann LLC||Article|
Mirati Therapeutics Executive Hires
|2016-01-11||Marcy Graham||VP Investor Relations/Corporate Communications||Article|
|2016-10-05||Chris LeMasters||Executive Vice President/Chief Business Officer||Article|